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 Economic evaluation of osteoporosis prevention and treatment 
ABSTRACT 
 
Osteoporosis is a major cause of morbidity, mortality and resource cost amongst the elderly 
population.  Hip fracture is the most serious of the osteoporotic fractures, with approximately 
10-20% of patients dying within six months of sustaining a fracture.  Furthermore, hip 
fractures are the most expensive manifestation of osteoporosis, incurring about 87% of the 
total costs of osteoporotic fractures.  This public health and economic burden is likely to 
increase in developed nations due, in part, to ageing populations.  In addition, there is strong 
evidence that the age-specific incidence of fracture is rising.   There are a number of 
treatments which can be used to prevent fracture including hormone replacement therapy 
(HRT), bisphosphonates, vitamin D and calcium.  These interventions have been used for 
primary prevention, secondary prevention and the treatment of established osteoporosis.   
 
This Discussion Paper details the results of a structured review, the purpose of which was to 
identify and critically appraise economic evaluations relating to interventions for 
osteoporosis.  The focus of the work is a critical assessment of the methodology of those 
studies.  A total of 16 economic evaluations was identified on the basis of a computerised 
search of three bibliographic databases.  All studies were based on decision analytical models 
and all took the form of cost-effectiveness analysis.  Seven studies were from the US and four 
from the UK.  The majority of studies focused on either primary prevention alone (seven) or 
both primary and secondary prevention where high-risk women were identified on the basis 
of bone mineral density screening (seven).  Most studies considered the cost-effectiveness of 
HRT.  
 
Most of the published studies conclude that treatment using HRT is relatively cost-effective 
among symptomatic women or women who have had a prior hysterectomy. In contrast, for 
asymptomatic women, the results are more equivocal. The most recent cost-effectiveness 
analysis was undertaken by the National Osteoporosis Foundation (NOF) which makes the 
explicit assumption that HRT is the treatment of choice.  For women unwilling or unable to 
take HRT, the next recommended treatment was alendronate; should alendronate not be 
tolerated, calcitonin was recommended.   
 
Many of the models included in the review exhibit methodological weaknesses which suggest 
their results should be treated with some caution.  One of these concerns the dearth of 
formally elicited health state preference data from patients or members of the public: only 
two studies in the review derive preferences empirically rather than use the authors’ 
judgement.  A second limitation of many studies is the inappropriate application of cost-
effectiveness decision rules with the frequent use of average cost-effectiveness ratios.  Areas 
of methodological controversy, such as whether or not to include costs unrelated to 
osteoporosis in life-years added as a result of treatment, increase uncertainty regarding how 
to interpret the results of the studies. 
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1.   INTRODUCTION 
1.1 Background 
Osteoporosis is a major cause of morbidity, mortality and cost amongst the elderly population 
[20].  The main population group affected by osteoporotic fractures is elderly, caucasian 
women.  The estimated remaining lifetime risk of fracture of 50 year old caucasian women 
has been estimated (from North American data) to be 17.5%, 15.6% and 16% for the hip, 
spine and forearm respectively [60].  Hip fracture is the most serious of the osteoporotic 
fractures, with approximately 10-20% of patients dying within six months of sustaining a 
fracture.  Furthermore, hip fractures are the most expensive manifestation of osteoporosis, 
incurring about 87% of the total costs of osteoporotic fractures [60].   
 
The financial cost to society of osteoporotic-related fractures is particularly large.  In the 
United Kingdom, it has been estimated that the cost of fractures occurring in women over the 
age of 50 is in excess of £700 million per annum [26].  In EU nations, the annual cost of 
osteoporosis has recently been estimated to exceed 9 billion ECUs [31], whilst in the USA 
the burden of fractures has been estimated at $13.8 billion [34].  These estimates may 
understate the problem as one of the most common fractures - vertebral - is rarely diagnosed.  
Despite this, such fractures will incur some costs to society through repeated physician 
consultations due to back pain, the use of pain relieving medications and increased use of the 
physical therapies and care services. 
 
This public health and economic burden is likely to increase in developed nations due, in 
part, to ageing populations.  In addition, there is strong evidence that the age-specific 
incidence of fracture is rising [44].  Furthermore, the public health impact of osteoporosis is 
probably greater than originally assumed as recent evidence suggests that, with the possible 
exception of skull fractures, most fractures occurring in elderly caucasian women are 
associated with low bone mass [45,58,71]. 
1.2.  Types of osteoporosis 
The World Health Organisation (WHO) [91] defines osteoporosis as: 
 
“a progressive systemic skeletal disease characterised by low bone mass and micro 
architectural deterioration of bone tissue, with a consequent increase in bone fragility and 
susceptibility to fracture” 
 
The WHO has based its definition of osteoporosis, and hence diagnosis, around the use of 
bone mineral density (BMD).  Bone mineral density is a normally distributed clinical variable 
and there is no obvious diagnostic risk threshold whereby fractures are more likely to occur.  
Despite this, the WHO has defined the following types of osteoporosis based on individuals’ 
BMD compared with that of the young normal mean.  Hence, low bone mass - or osteopenia - 
is said to be present if an individual’s BMD lies between -1 to -2.49 standard deviations Economic evaluation of osteoporosis prevention and treatment  2 
below the young normal mean (i.e. T-score of -1 to -2.49
1).  Osteoporosis, meanwhile, is 
diagnosed if BMD falls below a T-score of 2.5, whilst established osteoporosis is when an 
individual has a T-score of less than 2.5 and at least one documented fragility fracture, 
usually of the hip, spine or wrist.   
 
Whilst the above clinical definition has been accepted, it should be emphasised that, for the 
patient, low bone mass is asymptomatic, which, by itself, incurs no health-related quality of 
life (HRQL) penalty.  The act of measuring bone mass may, theoretically, detract from a 
person’s HRQL, by causing anxiety, if they are found to have low BMD.  However, the only 
empirical study which has attempted to measure this aspect of patient management detected 
no difference in anxiety levels between women with high and low bone mass [79].   
 
The most important aspect of osteoporosis is its clinical expression in terms of fractures, 
which are likely adversely to impact on patients’ HRQL.  Having low bone mass merely 
increases a patient’s relative risk of sustaining a fracture.  However, a patient with multiple 
fracture risk factors (e.g. low body weight, smoker, family history and prior fracture) may 
actually have a higher absolute risk of fracture compared with an individual whose only risk 
of fracture is low BMD.  From an economic perspective, this issue is important because it 
may be more cost-effective to treat an individual with multiple fracture risk factors compared 
with a patient with only one risk factor or low BMD.   
 
1.3 Preventing  osteoporosis 
There are a number of treatments which can be used to prevent fracture. These interventions 
have been used for one or more of the following roles
2: 
 
•  Primary prevention: in asymptomatic women with no apparent osteoporosis or elevated 
risk of the condition, to reduce their risk of its onset in later life. 
•  Secondary prevention: in asymptomatic women who have been shown to have BMD 
sufficiently low to place them at elevated risk of fracture, to slow down the decline (or 
restore) BMD and hence reduce the risk of fracture.  
•  Treatment: in women known to have osteoporosis and who have already experienced one 
or more fracture(s), to reduce the risk of further fractures.  
 
Table 1 summarises the effectiveness and UK costs of the most common anti-fracture 
treatments available.  Despite the clinically proven effectiveness of these treatments, they are 
probably underused.  For example, a recent study set within the UK showed that, even when 
women have had a clinically diagnosed vertebral crush fracture, less than 50% are offered a 
pharmaceutical therapy and, one year after fracture, 60% are not using any drug which 
                                                  
1 T-scores represent a number of standard deviations relative to a young adult normal mean.  The widely used 
alternative - the Z score - compares a person’s BMD with an age-adjusted mean.  Hence, the proportion of 
women defined as having low BMD by Z-score is constant, whilst with T-scores it increases with age. 
2 This approach to classifying prevention and treatment is widely used in the clinical literature.  In principle, the 
key distinction is between primary and secondary prevention, where the latter can be sub-divided on the basis of 
a continuum of risk factors. CHE Discussion Paper 169    3
beneficially affects bone metabolism [76].  In principle, preventive treatments can be used in 
this patient group: trial data for one of the bisphosphonates (alendronate) used on patients 
with established osteoporosis (i.e. 1 or more vertebral fractures plus low BMD), who were, 
therefore, at high risk of subsequent fracture, showed it to be statistically significantly more 
effective than placebo in reducing subsequent hip fracture [4].  Therefore, for alendronate at 
least, current evidence would suggest that it is a more effective treatment for patients with 
established disease.  Whilst HRT has been shown to be effective in a small trial among 
postmenopausal women with prior vertebral fractures [57], the most recent study of HRT 
failed to show any anti-fracture efficacy [47].   
 










HRT [57]  60% ↓ RCT  30-50% ↓ Hip, Colles 
CC 





        
Bisphosphonates        
Etidronate [74]  50% ↓ RCT  34% ↓ Hip, 19% ↓ 
Colles CC. 
£160 ? 
        






        
Calcium + vitamin D 
[16,18] 
31% ↓ RCT  30% ↓ Hip, 60%↓ all 




        
Calcitriol [75]  46% → 70% ↓ 
RCT 
50% ↓ Wrist RCT  £160 
 
Hypercalcaemia 
        
Calcitonin [66] 
 
75% ↓ RCT  24% ↓ Hip CC  Nasal*  ↓ acute pain 
        
Hip protectors [54]  N/A  50-70% ↓ Hip, RCT  £70 Uncomfortable  in 
hot weather 
 
*  Not available in the UK 
RCT = randomised controlled trial    CC = case control 
 
From an economic perspective, the choice of treatments for patients at risk is partly 
dependent on their cost.  Patients with established disease have a much higher absolute risk 
of fracture compared with patients who have osteoporosis or osteopenia.  Therefore, all 
things being equal, the cost per averted fracture will be lower among higher risk patients 
compared with those with a lower absolute fracture risk.  Hence, it makes sense from the 
perspective of costs, to target the most expensive treatments at those patients at highest risk.  
Furthermore, even if a treatment is relatively inexpensive, it may be best to reserve its use for Economic evaluation of osteoporosis prevention and treatment  4 
the highest risk patients if it has any undesirable side-effects.  For example, HRT increases 
breast cancer risk and alendronate is associated with gastrointestinal complaints.  If a 
patient’s absolute fracture risk is low, then giving these agents to such patients could be 
inefficient in the sense that they may reduce HRQL more from the side-effects than they 
increase it through fracture avoidance. 
 
1.4  Aims of the review 
Given the burden of osteoporosis, and the potentially widespread use of these interventions - 
many of which have high acquisition costs - for long periods of time, there has been a 
number of attempts over the last two decades or so to assess their cost-effectiveness relative 
to other uses of health care resources.  The increasing need for economic data, in some 
countries, to support applications for public reimbursement of pharmaceutical products is a 
further factor that has stimulated economic evaluation in this area [12,19].   
 
Economic studies in osteoporosis have been constrained by the availability of adequate 
clinical data, and they have typically taken the form of decision analytical models.  Models 
offer a valuable framework for synthesising clinical, resource use and valuation data from a 
range of sources, together with plausible assumptions, and for assessing the sensitivity of 
results to particular key parameters [2,6,30,42,72].  For interventions where clinical 
effectiveness has been measured over a relatively short period, but cost-effectiveness 
ultimately rests on long-term costs and benefits, models offer a means of extrapolating 
clinical measurements over time [11,70].  In addition, where measurement of effectiveness is 
in terms of intermediate clinical end-points (which predominate in regulatory drug trials), 
models can provide a way of making a link to the ultimate measures of benefit that are 
necessary for cost-effectiveness analysis, such as life expectancy or quality-adjusted life 
expectancy [11,70]. 
 
As for all types of economic evaluation, modelling-based analyses should be carefully 
assessed for the adequacy and appropriateness of their methods.  This is particularly 
important given the lack of consensus of what constitutes ‘good practice’ in many aspects of 
cost-effectiveness research [29].  Furthermore, many economic models are lacking in their 
clarity and the explicitness of their assumptions, and peer-review of this form of evaluation 
requires further development [73].  For these reasons, it is important that those seeking to 
draw policy conclusions from cost-effectiveness models, or to develop their own analyses in 
a given area, should be aware of the empirical and methodological strengths and weaknesses 
of published studies.   
 
This document details the results of a structured review, the purpose of which was to identify 
and critically to appraise economic evaluations relating to interventions for osteoporosis.   
The focus of the work is a critical assessment of the methodology of those studies.  The 
document is divided into the following sections. Section 2 details the methods used in the 
review.  Section 3 details the results of the review and is split into a brief summary of the 
studies identified in the review; a consideration of the empirical details of studies, in CHE Discussion Paper 169    5
particular relating to clinical assumptions and data sources; and the methodological issues 
raised by the studies.  Section 4 offers some conclusions.  Given their prominence, Section 3 
also contains a summary of, and comment on, the recent US guidelines for osteoporosis 
published by the National Osteoporosis Foundation. 
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2.  METHODS OF THE STRUCTURED REVIEW 
2.1 Inclusion  criteria 
All economic evaluations relating to osteoporosis were included.  The term economic 
evaluation was taken as including studies which have considered all the important costs and 
effects of an intervention in comparison with one or more relevant alternative(s), and which 
have made an attempt to present those data in such a way as to help decision makers establish 
their relative efficiency.  That is, they valued costs and effects in monetary terms to estimate 
net benefits (cost-benefit analysis), or they identified the clear dominance
3 of an intervention 
or expressed the differential effects of interventions on a single scale and related this to their 
differential costs (cost-effectiveness analysis).  Therefore, simple cost analyses were not 
included in the review. 
 
2.2  Search strategy and data extraction 
Published economic evaluations were identified from a computer search of three literature 
databases undertaken in September 1998: Medline from 1975 until the present; the NHS 
Economic Evaluation Database (Centre for Reviews and Dissemination, University of York); 
and the Office of Health Economics Health Economic Evaluation Database.  For Medline, the 
Mesh term ‘osteoporosis’ was used with the sub-term ‘economics’.  For the two specialist 
economic evaluation databases, the term ‘osteoporosis’ was used alone.  The titles and 
(where available) the abstracts of articles were studied by one reviewer (MS) and a decision 
taken as to whether the study was likely to fulfil the inclusion criteria of the review, in which 
case a full copy of the paper was ordered.  A definite decision was taken regarding inclusion 
on the basis of the detail provided in the full paper.  The reference lists of all included studies 
was also trawled for further studies. 
 
For included studies, information relevant to the review was extracted onto a pro forma by 
one of the authors (MS).  This was subsequently checked by a second author (RG) and 
differences settled by discussion.  This information was then summarised in data tables which 
provided the basis for the empirical and methodological assessment of the studies. 
 
                                                  
3 A dominant intervention is one that is less costly than all its comparators and at least as effective on all 
dimensions of effect, or no more costly and more effective on some dimensions of effect and no less effective 
on all others. CHE Discussion Paper 169    7
3.  RESULTS OF THE STRUCTURED REVIEW 
3.1 Overview 
A total of 16 economic evaluations was identified.  Table 2 provides a brief overview of 
each, and the appendix provides detailed data tables for all studies.  All studies were based on 
decision analytical models and all took the form of cost-effectiveness analysis.  Seven studies 
were from the US (five from the same team), four from the UK (two from the same team), 
two from Australia and one each from Denmark,  Sweden and Italy. 
 
The majority of studies focused on either primary prevention alone (seven) or both primary 
and secondary prevention where high-risk women were identified on the basis of BMD 
screening (seven).  Two studies looked at the cost-effectiveness of interventions to treat 
established osteoporosis.  The majority of studies considered the cost-effectiveness of HRT 
(11 studies included oestrogen replacement therapy (ORT), 10 studies considered combined 
(oestrogen plus progestogen) replacement therapy (CRT)).  Two studies included etidronate 
amongst their comparators (one considered bisphosphonates in general), three included 
calcitonin, two assessed calcium and one each considered vitamin D, vitamin D plus calcium, 
calcium plus exercise, fluroide, exercise and calcitonin plus calcium.  One study did not 
include a specific intervention but described a generic cost-effectiveness model for the 
evaluation of treatments for osteoporosis which was then used on notional interventions [50].  
 
Table 2.  Summary of studies in the review 
 
Study Country  Type  of 
prevention 
Interventions  Main stated conclusion 
Weinstein 
[1980] [85] 
USA Primary  and 
secondary 
ORT for 10 years, starting at various 
ages, in women with menopausal 
symptoms or women with symptoms 
of osteoporosis or all post-
menopausal women 
Treatment appears cost-effective in women 
with symptoms and osteoporosis with a 
prior hysterectomy. 




USA  Primary  Universal ORT or CRT during three 
alternative age ranges. 
Combined therapy seems cost-effective 
except in women who consider the effects 
of continued menstruation to be worse than 
the positive effects on menopausal 
symptoms 
        
Tosteson et al 
[1990] [81] 
USA Primary  and 
secondary 
No intervention, bone mass 
measurement and long-term CRT in 
high-risk women, universal CRT. 
Screening asymptomatic, perimenopausal 
white women to detect low bone mass and 
to target hormone replacement therapy at 
women with the greatest risk of fracture is 
reasonably cost-effective 




USA  Primary  ORT for 5, CRT for 5 or 15 years  The  cost-effectiveness  of  hormone 
replacement therapy compared favourably 
with other uses of health care resources but 
is very sensitive to quality of life effects. 
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USA  Primary  ORT vs no intervention (in women 
without uterus) and CRT vs no 
intervention (in women with uterus) 
ORT in hysterectomised women was 
considered cost-effective.  CRT in non-
hysterectomised women would probably 
only be cost-effective if it is used in 
women at high risk of hip fracture 
        
Daly et al 
[1992] [24] 
UK  Primary  ORT vs no intervention (in women 
without a uterus) and ORT vs CRT vs 
no intervention (in women with a 
uterus) 
Long-term prophylactic treatment of 
hysterectomised women and treatment of 
symptomatic women with a uterus is 
probably cost-effective 
 




Australia  Primary  ORT, CRT during three alternative 
age groups and no intervention.   
Hormone replacement therapy for 
symptomatic women is cost-effective 
when factors that enhance its efficiency 
are considered 
        
Geelhoed et al 
[1994] [39] 
Australia  Primary  ORT for various durations, dietary 
calcium supplements plus exercise, 
no intervention 
There is evidence to justify the 
introduction of treatment at later age 







Vitamin D, oral vitamin D and 
calcium in general population or 
those at high risk 
 








HRT in high-risk, HRT universally, 
no intervention 
Life-long therapy and treatment if high-
risk women is more cost-effective.  
        
Francis et al 
[1995] [35] 
UK  Treatment  CRT vs etidronate vs salmon 
calcitonin plus calcium 
HRT is the treatment of choice for post-
menopausal women with osteoporosis. 
        
Jonsson et al 
[1996] [50] 
Sweden  Treatment  Treatment for 5 years for 62 year-old 
woman with low BMD vs no 
treatment 
Similar cost-effectiveness ratios to the 
management of mild hypertension were 
shown 








Calcium, etidronate, calcitonin, HRT  Prevention of osteoporosis through 
screening for low BMD should not be 
recommended at the moment. 
        
Daly ey al 
[1996] [25] 
UK  Primary  ORT vs no intervention (in women 
without uterus) and CRT vs no 
intervention (in women with uterus) 
Assuming that ORT offers cardiovascular 
benefits, long-term prophylactic treatment 
of hysterectomised women would be very 
cost-effective; lack of data on the effects 
of CRT on cardiovascular disease make a 
conclusion about HRT on non-
hysterectomised women more difficult. 
        





Calcitonin for  1year vs no treatment  HRT appears to be the best option at 
present for hip fracture prevention. 





USA  Secondary  HRT, calcium, Vitamin D, 
Calcitonin, bisphosphonates, fluoride, 
exercise 
BMD testing should be undertaken on the 
basis of other risk factors. HRT is the most 
cost-effective intervention, but its 
optimum use depends on risk factors. 
ORT = Oestrogen replacement therapy        CRT = Combined (oestrogen plus progestogen) replacement therapy 
HRT =  Hormone replacement therapy        BMD = bone mineral density CHE Discussion Paper 169    9
3.2 Empirical  results 
Table 2 details the main conclusions of each of the studies in the review. 
3.2.1  Evaluations of hormone replacement therapy 
Background.  Hormone replacement therapy (HRT) is the oldest and most widely evaluated 
(in economic terms) of the osteoporosis treatments.  Indeed, before 1990 no other 
intervention for osteoporosis had been subject to cost-effectiveness analysis [78].  However, 
more recently, other treatments have been licensed in this area and scrutinised with respect to 
their cost-effectiveness. 
 
Evaluating the cost-effectiveness of HRT is difficult for three reasons.  Firstly, its effects are 
multi-systemic with a putative range of health benefits and disbenefits. Secondly, there is a 
paucity of randomised trials which have been adequately powered to detect clinically relevant 
endpoints (e.g. fracture reduction).  Although synthesis of observational studies suggests 
HRT offers a survival benefit [43], this has yet to be demonstrated in trials.  Large trials are 
underway to evaluate HRT in the USA and UK [92].  Thirdly, no RCT has included a 
contemporaneous economic evaluation.  Furthermore, some of the assumptions underlying 
most of the economic models of HRT have been questioned.   
 
The traditional clinical model for using HRT to prevent osteoporotic fractures is that women 
would be offered HRT at the menopause (at about 50 years), with a recommendation that 
they take the hormone for 5 to 10 years.  The idea behind this approach was that the median 
age of hip fracture was about 80 years and, if 5 to 10 years of HRT could delay the time to 
hip fracture by a corresponding amount, then most women would have reached the end of 
their natural life span before enduring a hip fracture.  Even if this model were correct from a 
clinical perspective, it has some important implications economically due to the effect of 
discounting future costs and benefits [15].  In particular, most of the costs of prevention 
would be incurred 20 to 30 years before the benefit in terms of fracture prevention.   
Furthermore, some of the unwanted side-effects of treatment (e.g. increased risk of breast 
cancer) would occur long before the benefits of treatment, thus the relative importance of 
these side-effects would be accentuated through discounting.   
 
Within the last 10 years some of the key assumptions underlying the clinical model of HRT 
have been undermined.  Recent  observational data strongly suggest that the effects of HRT 
do not persist in the long-term - that is, the beneficial effects on bone are lost shortly after 
cessation of treatment [14,62].  Thus, for treatment to be effective at preventing fractures, 
continuous and life-long use is required, which will greatly increase costs and the risk of 
breast cancer, the latter likely to be detrimental to treatment compliance.  Additionally, a 
large randomised trial of HRT, which was designed to show a benefit to the cardiovascular 
system, failed to show any effect despite four years of treatment [47].  These most recent data 
cast doubt upon the cost-effectiveness of long- term use of HRT.   
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The association between BMD and breast cancer risk has important implications for the cost-
effectiveness of HRT.  Evidence from observational studies and the latest trial by Hulley et al 
[47] suggest that HRT is associated with a 30% increased risk of developing breast cancer.  
On the other hand, two recent observational studies strongly suggest that women at very high 
risk of osteoporosis (i.e. those with a BMD Z score of about -0.7) have a substantially 
reduced absolute risk of breast cancer [13,95].  Thus, women with low bone mass are likely 
to benefit more from HRT use through a greater reduction in the absolute risk of fracture, but 
with a smaller increase in the absolute risk of breast cancer.  For a woman whose BMD is in 
the lowest quartile, then even if HRT increases the relative risk of cancer by 30%, her 
absolute cancer risk will still be less than an untreated woman with high BMD, if HRT 
increases breast cancer risk by the same relative amount regardless of underlying risk.  Only 
if HRT selectively increases breast cancer risk for women at low absolute risk of the disease 
will the use of BMD  measurements not improve cost-effectiveness, in terms of breast cancer 
risk.  
 
HRT is multi-systemic in its effects.  In the following we consider the implications of this for 
cost-effectiveness models.  
 
Health-related quality of Life (HRQL).  Improving HRQL - or, to be precise, individuals’ 
valuation of that improvement in terms of utilities - is, along with extending life, a key 
objective of any treatment.  Given that all the studies in the review were based on models, the 
term HRQL is used here to refer to the values that have been ascribed to individuals’ 
preferences for health states that are expected to change as a result of the interventions being 
evaluated.  Clearly, there will be a gain in HRQL by avoiding fractures and other clinical 
events.  Conversely, there may be a reduction through side-effects of treatment.  This section 
considers some of the important empirical HRQL issues and whether the published studies 
have addressed them.  Later we consider some methodological issues regarding utility 
elicitation in this clinical area. 
 
Most treated women will not benefit from HRT for fracture or cardiovascular protection 
because, without treatment, only a minority would have a preventable fracture or cardiac 
event.  Therefore, it is important that any side-effects of treatment on HRQL are taken into 
account.  All the studies identified in the review included a utility for relief of menopausal 
symptoms with the exceptions of Geelhoed and Harris [39], the OTA [83] and Tosteson et al 
[81].  Apart from Daly et al [25], none of the utilities was derived empirically (that is, they 
were based on the authors’ judgement and were generally taken from Weinstein’s original 
study [85]).   
 
However, the use of utilities for menopausal symptoms when evaluating HRT for use as a 
preventive treatment for osteoporosis needs to be treated with some care.  This is because, for 
women with menopausal symptoms, the key question is whether the costs of hormonal 
treatment will be justified by the benefits in terms of alleviation of menopausal symptoms.  
Two studies - Daly et al [22] and Zethraeus [94] - indicate that, for this purpose, HRT is a 
relatively cost-effective use of resources.  Therefore, women with menopausal symptoms, CHE Discussion Paper 169   11
with no medical contra-indications for treatment, are very unlikely to be denied HRT.  In 
contrast, the decision regarding the use of HRT for osteoporosis prevention is an incremental 
one of what benefits the patient will receive over and above that of menopausal symptom 
relief, and at what cost.   
 
The only cost-effectiveness study which has explicitly excluded HRQL gains is by Tosteson 
et al [81].  Indeed, they prudently include HRQL adjustment for the possible detrimental 
effects of adding progestogen, although trial data, published since they undertook their 
evaluation, suggest that HRT with progestogens does not adversely effect HRQL [59]. 
 
For HRQL effects from fractures, the studies have tended to use Weinstein’s original 
estimates [85]; a small number have used values from Hillner et al which were also based on 
the authors’ judgements [46].  More recently, the National Osteoporosis Foundation (NOF) 
guidelines have used a panel of experts approach to derive utility values for fractures [64].   
However, this approach using panel ‘surrogate’ estimates for utilities can be criticised in that 
they may not reflect patients’ or the public’s valuations.  This can be illustrated by a recent 
empirical study of the effect of Colles fracture on utility which produced a value 
approximately half of that used by the National Osteoporosis Foundation [27].   
 
Curiously, no study has attempted to reflect HRQL loss due to breast cancer, focusing instead 
on its mortality effects.  This is an important omission given that 70% of breast cancer 
patients will survive for at least five years after diagnosis.  Thus, not including a utility for 
the non-mortality effects of breast cancer will tend to overestimate the cost-effectiveness of 
HRT.  Similarly, only one study (Cheung and Wren [17]) tried to include the HRQL effects 
of avoiding cardiovascular disease.  In contrast, a number of studies have included utility 
weights for the relatively rare event of endometrial cancer.  
 
As stated above, Tosteson et al [81] examined the effects of reductions in HRQL due to 
treatments.  Jonsson et al’s model demonstrated the importance of negative side-effects of 
treatment [50].  If  treatment reduces HRQL by 1% or more, then the disbenefits of therapy 
would dominate.  Therefore, it is important to quantify and value the HRQL implications of 
the side-effects of treatment.  As discussed further in the methodological section below, the 
utility data used in the models is one the major areas of weakness. 
 
Clinical events.  Most studies have made the assumption that use of HRT reduces hip 
fractures in the order of 50%.  However, this effect size is purely based on observational data, 
as only one small RCT of HRT has ever shown a reduction in fractures, and these were 
vertebral fractures [57].  An important effect to consider in evaluations of fractures is how 
long the effect of the agent persists after cessation of treatment.  There is a view that there is 
a “catch-up” in bone loss after cessation of treatment which has been suggested by one study 
[55].  Thus, after cessation of treatment, bone loss is increased over and above that which 
would be expected if treatment had not taken place so that, 2 to 3 years after treatment, a 
patient is in the same position as an untreated patient.  The view of rapid catch-up is disputed, Economic evaluation of osteoporosis prevention and treatment  12 
but it seems likely that bone loss is somewhat accelerated, such that little benefit is seen 10 to 
15 years after treatment [33]. 
 
Ideally models should take into account the fact that non-fracture mortality risk is increased 
among women with low BMD [10].  This will reduce the long-term effectiveness of 
treatment, as a higher proportion of treated women will die from other causes and will not 
live to enjoy the benefits of avoiding fractures.  None of the evaluative studies in the review 
has reflected this mortality characteristic. 
 
Most of the published studies conclude that treatment using HRT is relatively cost-effective 
among symptomatic women or women who have had a prior hysterectomy.  A recent review, 
which standardised the incremental cost per QALY ratios of published studies to $US and a 
common price year, showed that the cost per QALY gained ranged from $12,000 to $23 000 
[78].  The exception to this was the study by Daly et al which used assumptions of larger 
QALY gain from relief of menopausal symptoms and produced a cost of $3,000 per QALY 
gained [25].   In contrast, for asymptomatic women, the results are more equivocal.  The cost 
per QALY ranges from $26 000 to $52 000, with Weinstein [85] concluding that the 
disbenefits outweighed the benefits (i.e. dominance).   
 
3.2.2  Non-HRT treatments for fracture prevention 
Fewer evaluations have been published on non-HRT treatments.  This is partly because it is 
only relatively recently that evidence has emerged that there are non-HRT alternatives for 
fracture prevention.  Non-HRT treatments have a number of advantages over HRT, not least 
that most can be used to treat men.  From a modelling perspective, treatments such as the 
bisphosphonates, calcium and calcitonin require fewer assumptions with respect to extra-
skeletal treatment effects.  The dominant clinical effects of these treatments lie in their ability 
to prevent fractures, although some treatments such as alendronate may require models to 
include some HRQL weights to take into account unwanted gastrointestinal effects.  In 
addition, other compounds, such as calcium and vitamin D, have relatively robust trial 
evidence to support their effectiveness assumptions - unlike HRT. 
 
The simplest models of therapies include Francis et al [35] and Torgerson and Kanis [77].  
Francis  et al reviewed the evidence with respect to the effectiveness of a number of 
treatments for preventing vertebral fractures.  They then simply divided the annual purchase 
cost of the compound by the estimated absolute reduction in vertebral fractures.  Whilst this 
study has the merit of being simple there are a number of criticisms.  One of the main 
problems is using the cost per averted vertebral fracture, which makes the results difficult to 
compare with other evaluations outside the area of osteoporosis prevention.  Furthermore, the 
study used changes in all vertebral fracture rates, not simply reductions in clinically apparent 
vertebral fracture.  A major problem with this approach is that the majority of vertebral 
fractures are asymptomatic and, as such, do not cause the patient much in the way of HRQL 
loss.  It would have been better to estimate a cost per averted clinical fracture as these have 
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The study by Torgerson and Kanis did include some estimate of averted fracture cost [77]; 
however, a similar criticism can be applied to it as to the Francis et al study in that the 
denominator in the cost-effectiveness equation was fractures averted (in this instance hip) 
rather than a more useful measure of quality-adjusted life-years (QALYs).  Furthermore, the 
conclusions of the study that vitamin D alone is highly cost-effective has not been borne out 
by the latest clinical trial of vitamin D [56].  However, the study does make the valuable 
point that, for pharmaceutical preparations of calcium and vitamin D to achieve a reasonable 
cost-effectiveness ratio, targeting patients at high risk of fracture is desirable.   
 
Geelhoed and Harris [39] is one of the few studies to consider non-HRT treatments - in this 
instance life-long use of calcium and exercise - for all postmenopausal women.  In their 
model, calcium and exercise did not appear particularly cost-effective.  However, a better 
comparator would have been for calcium supplementation to begin in later life, as they 
modelled HRT.  This would have improved significantly its cost-effectiveness ratio.   
However, the conclusions of studies by Geelhoed and Harris, and the OTA [83], that it is 
more cost-effective to commence treatment later in life with a bone sparing compound, is 
likely to be correct. 
 
3.2.3  The National Osteoporosis Foundation Guidelines 
The most recently published economic evaluation is contained within the NOF’s clinical 
guidelines for the USA [64].  This represents a comprehensive set of guidelines for the 
diagnosis and treatment of osteoporosis and, given their high profile in the “bone 
community”, we have chosen to explore their model in more depth. 
 
The NOF guidelines make the explicit assumption that HRT is the treatment of choice.  For 
women unwilling or unable to take HRT, then the next recommended treatment is 
alendronate; should alendronate not be tolerated, calcitonin is recommended.  By using this 
approach, the NOF makes the assumption that the comparator treatment in all instances is ‘do 
nothing’.  Furthermore, it is assumed that all patients are given calcium supplementation.  
Other treatments, such as fluoride, are not evaluated on the grounds that there is insufficient 
evidence as to their effectiveness. 
 
A key parameter affecting the NOF’s cost-effectiveness model is the use of the Study of 
Osteoporotic Fracture (SOF) dataset for risk factors for fracture [21].  The risk factors used to 
target diagnosis and therapy were low body weight, prior fracture, family history and 
smoking status.  The guidelines suggest targeting diagnostic and treatment resources at 
patients with one or more of the preceding risk factors.  Whether these risk factors can be 
applied to a European population is unknown.  Furthermore, the SOF population were all 
aged 65 and over, so it is doubtful if all these risk factors are relevant for younger 
postmenopausal women.  
 
With respect to evaluating HRT, the NOF guidelines only consider HRT’s effects on 
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justifiable not to include cardiovascular endpoints, particularly given the results of the most 
recent randomised trial [47],
 it is of some concern that breast cancer effects are not included.  
Not including breast cancer effects will improve the cost-effectiveness ratios compared with 
other interventions.  In addition, as mentioned previously, their assumptions about the utility 
loss associated with various types of fracture were derived from a consensus panel rather than 
empirically from patients or the public. 
 
A problem with applying the NOF guidelines to the UK or Europe is the use of US cost data, 
which certainly differs from the UK.  For example, the price of calcium supplementation used 
by the NOF was $50 annually; however, in the UK pharmaceutical preparations of calcium 
are about £100.  In contrast, the NOF price HRT treatment in excess of $400 annually, whilst 
the cheapest UK HRT regime is less than £25.  Thus, the NOF analysis makes calcium 
supplementation for the entire population appear relatively cost-effective whilst HRT is 
reserved for highest risk women.  Furthermore, their costs of bone density scans are relatively 
high compared with the UK costs and their costs of fractures are greater.   
 
Finally, with respect to the use of bone density measurements, the NOF assumes an 
unrealistic 100% compliance after measurement.  Again, this assumption will tend to cast the 
cost-effectiveness of diagnosis and treatment of osteoporosis in a favourable light. 
 
3.3 Methodological  issues 
A range of methodological issues relating to modelling-based economic evaluations of 
osteoporosis interventions has emerged during this review.  Most of these issues are 
discussed across the reviewed studies in general, although illustrations will be made by 
referring to particular studies. 
 
3.3.1  Types of models 
The most frequently used model in the studies that have been reviewed is the state transition 
model.  The advantage of this type of decision model is that it deals explicitly with time, 
which is important for chronic conditions such as osteoporosis. The state transition model 
takes the form of a series of states which relate to particular clinical or resource consumption 
events.  Typically, a hypothetical cohort of patients enters the model and, over a series of 
cycles representing a period of time such as a year, patients make transitions between states 
and, in the process, accumulate costs.  The pattern of transitions, over a number of years, 
facilitates an estimate of expected costs.  One of the states is usually death, and the timing of 
transitions to that state allows an estimate of life expectancy.  Probably the most popular 
form of state transition model in economic evaluation is the Markov model, where transitions 
depend only on the current state and are not influenced by earlier states [6,72]. 
 
A baseline model reflects the risks of clinical events, such as fracture, that women face in the 
absence of preventative interventions.  The risks take the form of transition probabilities 
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impact of a particular intervention on costs and outcomes, the model is effectively re-run 
using a second set of transition probabilities which reflect the relative risk of clinical events 
under that treatment regimen.  In other words, the effectiveness of the intervention manifests 
itself in the model by modifying some or all of the baseline transition probabilities. 
 
State transition models can be characterised by transition probabilities that are fixed with 
respect to time.  In the case of models for osteoporosis interventions, the key influence of age 
on clinical risks means that fixed transition probabilities are not a reasonable representation 
of clinical reality.  Therefore, most of the state transition models reviewed here have defined 
their transition probabilities as a function of age. 
 
Relatively few studies in the review have explicitly described the structure of their models - 
that is, defining their states and the probabilities of transition between them.  One of the 
clearer expositions of model structure is offered by Tosteson and Weinstein [82]. The 
structure of Tosteson and Weinstein’s model serves as an illustration of how various authors 
have tackled the problem.  The key states in the model were: 
 
•  well and living in the community; 
•  hip fracture; 
•  nursing home; 
•  disabled and in nursing home; 
•  breast cancer ; 
•  ischaemic heart disease; and 
•  dead. 
 
With the exception of the disabled and living in a nursing home state (which was arrived at 
only after a hip fracture) and the dead state (which is a natural absorbing state from which no 
transitions are possible), transitions between all other states were feasible.  All transition 
probabilities were set up as being age-dependent.  Costs were attached to each state and, for 
states where patients could remain for a number of cycles of the model (most notably the 
nursing home state), costs were ‘run-up’ every cycle. 
 
Other state transition models in the review included other states by virtue of including 
different effects (the effects included in each study are detailed in Column 4 of the Data 
Tables in Appendix 1).  For example, a number of studies included an endometrial cancer 
state, some modelled several types of fracture separately and some studies evaluating HRT 
included a state for gallbladder disease. 
 
In general, the baseline transitions between states are a function of estimates of the incidence 
of clinical events or, in the case of transition to the ‘dead’ state, of the mortality rates 
assumed for women in general and for those experiencing particular clinical conditions 
(Column 5 in the Data Tables in Appendix 1).  The effectiveness of interventions (Column 6 
in the Data Tables) is used to modify these baseline transition probabilities for the treatment 
models.  Although there are clear methods of how information on rates should be translated Economic evaluation of osteoporosis prevention and treatment  16 
into probabilities [63], none of the papers detail how they have estimated probabilities from 
data on rates. 
 
State transition models are particularly valuable when the natural history of a condition and 
the effects of an intervention need to be characterised over a considerable period of time, or 
when there is a number of possible health events to be modelled.  The review shows that this 
made state transition models particularly popular in evaluations of HRT, where treatments 
were typically assumed to be long-term and the intervention generated a series of competing 
risks.  In contrast, several studies of non-HRT interventions, such as vitamin D and 
calcitonin, where extra-skeletal effects are not relevant and where treatment was assumed to 
be shorter in duration, required much simpler forms of models.  These models could be 
described as simple decision trees, although they were rarely defined in those terms in the 
papers.  This applied in particular to studies using cost per fracture avoided as their 
representation of cost-effectiveness [35,77]. 
 
As a general point relating to the modelling studies in the review, the complexity of the 
clinical area - particularly in relation to HRT - often precluded full and explicit details of the 
model.  This was particularly the case when the study was published in a clinical journal, as 
most of them were, with consequent limitations on space.  The result of this was that many 
models took on the appearance of a ‘black box’, lacking the clarity for the reader that has 
been urged for model-based economic evaluations [11].  One way around this problem is for 
authors to make available a technical report giving full details of the model and general 
methods, but this approach does not seem to have been used by authors of papers in the 
review. 
 
In recent years, state transition models have more frequently been stochastic in nature; that is, 
transition probabilities and other parameters have been set up as distributions rather than 
point values for a given age group [42].  This has the advantage of the estimates of cost and 
effect (and hence the incremental cost-effectiveness ratios comparing management strategies) 
including both averages but also a measure of uncertainty - usually in the form of a 95% 
confidence interval.  Only one study in the review included a stochastic analysis [83], which 
took the form of a first-order Monte Carlo simulation [6].  The approach provides an 
additional way of expressing uncertainty in cost-effectiveness estimates, but it remains 
unclear whether this makes the analysis more persuasive to decision makers.  There are also 
limitations to stochastic analysis, such as the need for greater information about the inter-
relationships between variables [42].  In general, however, as more information becomes 
available on the distributions of key clinical parameters, this should be reflected in the 
structure of decision models. 
 
Some additional aspects of the models can usefully be mentioned.  An important issue 
regarding the effectiveness of preventive therapies for osteoporosis - particularly those that 
the patient is expected to take for a considerable period - is the extent to which the patient 
complies with therapy [3].  From the viewpoint of the cost-effectiveness of treatments which 
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absence of compliance is usually assumed to result in no costs (because the medications are 
not actually prescribed) and no additional benefits.  In other words, non-compliant patients 
take on the characteristics of a patient in the usual care or control arm of a study.  In effect, 
this means that the cost-effectiveness of the interventions in the review are assessed when 
they are fully complied with by patients, but that reducing compliance rates is unlikely to 
effect cost-effectiveness ratios markedly.  The only situation when this assumption would 
seem unrealistic is when non-compliance takes the form of medication being prescribed to 
patients by the patient not actually taking them - they flush the tables down the toilet, for 
example.  In this context, the costs of the drugs are incurred but the benefits that may be 
derived from their consumption are not realised, and this has the effect of ‘watering-down’ 
the benefits experienced by compliant patients.  All the models in this review assumed that 
non-compliance resulted in zero costs and zero additional benefit, which is the same as 
assuming 100% compliance. 
 
However, as noted above, the assumption of 100% treatment compliance on the part of high-
risk patients who are identified using screening may have implications which cast doubt on 
the validity of the assumption.  This is because screening represents a cost for all patients 
regardless of whether they then comply with treatment.  If patients are screened and then do 
not take treatment when they are identified as high risk, there is no chance of benefits being 
generated (in the form of improved HRQL and reduced mortality) to justify the cost of the 
screening.  In this context, the cost-effectiveness of screening plus treatment of high-risk 
patients is likely to be quite sensitive to assumptions regarding treatment compliance.   
However, studies in the review which evaluated this form of management usually assumed 
100% compliance and did not undertake detailed sensitivity analysis of the parameter. 
 
Another important characteristic of the models was the link that was often made between 
BMD and fracture risk in the context of HRT evaluations.  Given the lack of experimental 
data directly linking HRT use with a reduction in fracture risk, many studies of agents 
affecting bone metabolism have used changes in BMD to infer changes in fracture risk.   
However, there have been a number of recent trials which have shown that changes in BMD 
may not relate to changes in fracture risk.  For example, Lips et al showed a 20% increase in 
fracture rates (not statistically significant) in a randomised trial of vitamin D supplementation 
despite a significant increase in BMD in the treated groups [56].  On the other hand, a 
randomised trial of calcium and vitamin D showed large reductions in hip fracture risk 
despite only a relatively slight increase in BMD [16].  This unclear relationship between 
changes in BMD due to treatment and fracture risk has important implications when using 
BMD in modelling studies, as any inferences between changes and BMD are uncertain.   
Thus, relying on changes in BMD to inform assumptions with respect to fracture risk may 
either under estimate or over estimate the effectiveness of any given compound. 
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3.3.2 Costs 
An important characteristic of an economic evaluation is the perspective it takes on costs and 
benefits [28].  All studies in the review focused on the patient’s perspective on the outcomes 
side, which is typical of economic evaluations in general; that is, the studies focused on 
changes in mortality and morbidity to the women themselves rather than the effects this 
might have on other members of the community.  On the cost side, most studies adopted the 
perspective of the health service or payer.  At a level of principle, this may be considered a 
weakness of studies in this area.  Undoubtedly, the clinical implications of osteoporosis, and 
of interventions to prevent and treat it, will have cost implications outside the health service, 
most notably for patients themselves and their friends and relatives in the form of lost income 
and out-of-pocket costs.  At the level of principle, the societal perspective, which includes all 
costs no matter on whom they fall, is preferable to that of the health service, as it is less 
arbitrary, can reflect any costs that are been ‘externalised’ on others and is more faithful to 
the tenets of applied welfare economics [48].   
 
However, some have argued that inclusion of non-health care costs in cost-effectiveness 
analyses is inappropriate as the opportunity cost of those resources includes more than just 
health outcomes which is the focus of this form of economic evaluation [40].  In addition, 
there have been recent methodological disagreements in the literature about the appropriate 
approach to valuing productivity changes - one possible component of non-health service 
costs [8,9,87].  Recent recommendations for ‘good practice’ in cost-effectiveness analysis, 
however, have emphasised the need to include costs across society, at least in a reference 
case analysis [42].  In the studies reviewed in this document, only one considers costs outside 
the health service [50].  Given the direction of ‘good practice guidelines’ in this area, future 
modelling work in osteoporosis will probably need to take a broader perspective on costs 
than most studies to date. 
 
On the whole, the estimation of cost parameters in the models in the review was undertaken 
crudely.  As an example, Daly et al used average lengths of hospital stay (by age group) for 
particular conditions, such as hip fracture, and an average cost per in-patient day across 
specialities as their basis of costing [23,25].  This approach ignores differences in costs per 
day and non-hospital costs.  Whilst this lack of sophistication is not surprising given the large 
number of cost parameters required for HRT models and the dearth of good-quality cost data 
in most health care systems, there may be an effect on the acceptability of the studies to 
decision makers.  This may have been accentuated by a focus on average, rather than 
marginal, costs [78].  In recent years, more detailed cost estimates have become available of 
clinical events relating to osteoporosis (most notably fractures [34,93]).  Hence, future 
modelling studies in this area should be able to reflect a greater degree of accuracy in their 
cost parameters. 
 
Another aspect of costing methodology in the papers covered in the review should be 
mentioned, namely the issue of whether to include the cost of health care, unrelated to 
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been a dispute for some years as to whether these costs should be included [69,88].  The 
recent methods literature has offered a more theoretical insight into the issue [38,61], but no 
consistent conclusion has been reached regarding inclusion or exclusion.  The US Panel 
reflects this uncertainty and does not take a firm position on this point, although they note 
that whether or not to include can, in certain situations, have a marked effect on the results of 
studies [42]. 
  
In general, very few economic evaluations include unrelated health care costs incurred 
through helping people to live longer.  However, it is interesting to note that the studies by 
Daly et al do include these costs [23,25], estimating them on the basis of age-adjusted lengths 
of hospital stay multiplied by an average cost per day in hospital.  Whilst the authors are not 
clear about the sensitivity of their results to the inclusion of these costs, the effect of 
discounting may minimise their importance in studies with a long time horizon.  However, in 
recent years, it has been felt that preventive treatments for osteoporosis can be given later in 
life, when fractures are most likely to incur, thus shortening the time horizon of studies.  In 
this context, the inclusion of unrelated costs in added life-years may be more critical.  This is 
an area of methodology that future developers of models in osteoporosis will need to consider 
carefully. 
 
3.3.3 Decision  rules 
A crucial stage in a cost-effectiveness analysis is the process by which data on the costs and 
effectiveness of individual and mutually exclusive interventions are compared and used to 
identify the most cost-effective option.  Although these ‘cost-effectiveness decision rules’ 
have been detailed in the health care literature for some time [90], they have frequently been 
misapplied in studies [49].   
   
The inappropriate use of decision rules is particularly widespread in cost-effectiveness 
studies in osteoporosis on the basis of this review, as noted in the comments section of the 
Appendix.  Most of the studies in the review compare a number of mutually exclusive 
management options which differ according to factors such as the actual intervention (e.g. 
type of drug) and the duration of the treatment.  In this multiple option context, the 
appropriate approach to identifying preferred options in cost-effectiveness analysis can be 
summarised in the following steps [49,52]: 
i.  rank all mutually exclusive management options in terms of their cost; 
ii. exclude all options that are subject to dominance (more costly and less effective than at 
least one other option) or extended dominance (have a higher incremental cost-
effectiveness ratio than a more effective intervention); 
iii. calculate the incremental cost-effectiveness ratios of all remaining options relative to the 
next least effective; 
iv. identify the highest incremental cost-effectiveness ratio that can be funded by considering 
similar ratios for independent options as calculated in other studies and which may have 
been funded by the health care system, or by employing a maximum willingness to pay 
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A number of studies in the review do not go through this formal process, often calculating 
average, rather than incremental, cost-effectiveness ratios, which compare the cost and effect 
of each management option with a notional ‘no intervention’ and compare these ratios across 
all options under consideration.  This is an area where future studies should attempt to adhere 
more strongly to established methodology.  
 
3.3.4  Health state preferences 
Section 3.2 above discusses some of the empirical issues related to how HRQL has been 
valued, in terms of health state preferences or utilities, in studies identified in the review.  
This section considers the methodological issues that are raised.  It should be emphasised 
that, because all the studies in the review were modelling studies, there was no process of 
HRQL measurement using recognised descriptive instruments, whether generic or disease-
specific.  Rather the general aim was to ascribe utilities to the various health states that were 
incorporated into the models. However, this process has generally been undertaken without 
formal utility elicitation from patients or the general public.  Authors of most of the early 
studies have used the utilities adopted by Weinstein [85], but these were based solely on the 
judgement of the author himself.  Some studies have sought to be rather more rigorous in 
their choice of utilities by adopting those detailed by Hillner et al  which ‘were determined 
by a consensus of the persons working on the model and were reviewed by an expert panel’ 
[46] (p.1119).   
 
These approaches to utility estimation do not adhere to what is generally considered good 
practice [42,67].  Few methodologists working in this area would consider an author’s 
judgement as an adequate source of utility data.  Several formal utility elicitation tools are 
available, such as the standard gamble, time trade-off and rating scale [67,80], with 
economists often expressing a preference for choice-based elicitation techniques [5,65].   
Although utilities are frequently elicited from patients for cost-effectiveness analysis, many 
economists would argue for the need to use public preferences in studies which are being 
used to assist allocation decisions for public resources [37].  In part, this is what lays behind 
the recent development of multi-attribute utility scales, such as the EuroQol (EQ-5D) [53] 
and Health Utilities Index [32].  These instruments are characterised by a general descriptive 
system, which generates a number of health states into which patients can be classified at 
intervals in prospective studies, and a tariff of utilities relating to each health state, based on 
utility elicitation exercises with members of the public.  Incorporation of preference data into 
studies on the basis of these instruments was an important recommendation in recent 
guidelines for cost-effectiveness analysis [41].   
 
Some of the later studies in the review have begun to incorporate stronger methods for HRQL 
valuation.  Daly et al’s second analysis [25] incorporated the results of a utility elicitation 
exercise with 63 women who were presented with descriptions of mild and moderate 
menopausal symptoms [22].  A limitation of the study, however, was that HRQL adjustments 
related only to menopausal symptoms, and not to fractures, hysterectomy, breast cancer, 
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of possible interventions to prevent fracture in established osteoporosis, utility effects of 
fracture were based on Hillner’s judgements [46], but also on the utilities suggested by the 
Rosser multi-attribute scale [68], based on the original utility tariff and an alternative 
developed by the authors. 
 
Although some of the later studies in the review looking at the cost-effectiveness of 
interventions for the prevention and treatment of osteoporosis incorporated utility data based 
on formal elicitation exercises, it can be argued that, in general, HRQL valuation methods 
were one of the weakest aspects of the studies in the review.  This weakness partly reflects 
the methods used to ascribe utilities to clinical events, and partly to the fact that the HRQL 
implications of some events were not estimated at all (in particular, breast cancer - see 
Section 3.2 above).  The utility effects of clinical events should be an important area of focus 
in future modelling studies in this area. 
 
3.3.5 Handling  uncertainty 
A very clear characteristic of the studies in the review is the multiple sources of uncertainty 
that they exhibit in their results.  As for all economic evaluations [7], these sources of 
uncertainty can be placed into four categories: 
 
•  uncertainty relating to data inputs - for example, the relative risk of fracture with particular 
interventions, the utility weight associated with particular clinical events and the cost of 
events; 
•  uncertainty relating to analytical methods and assumptions - for example, the discount rate 
employed; 
•  uncertainty relating to extrapolation - for example, the assumptions used to predict 
prognosis with and without HRT outside the period of primary studies from which data 
were taken, such as those relating to what happens to BMD after HRT therapy is 
discontinued; 
•  uncertainty relating to generalisability - for example, the extent to which a study 
undertaken in the USA has relevance to Europe. 
 
In virtually all studies that tried to assess the importance of uncertainty, sensitivity analysis 
was the main tool employed.  Most studies employed a mixture of simple one-way sensitivity 
analysis, where one parameter at a time was altered and its effect on the cost-effectiveness 
results assessed, and scenario analysis where a series of related parameters was altered 
simultaneously.  As mentioned above, only one study employed a stochastic approach to 
dealing with uncertainty [83], although this is likely to have a more prominent role in future 
modelling studies.   
 
Whilst one-way sensitivity and scenario analysis are valuable tools in assessing some forms 
of uncertainty in economic analysis [7], they are not easily employed to evaluate the 
structural assumptions contained in a model, such as the speed with which BMD declines 
after treatments are discontinued and the assumption that women with low BMD, who do not 
experience particular clinical events, have the same age-specific mortality risks as the general Economic evaluation of osteoporosis prevention and treatment  22 
female population.  This is because these assumptions may be rooted in the programming for 
the model and are difficult to alter.   
 
The inevitable requirement in modelling studies to make structural assumptions has led to a 
recent interest in how decision models used for cost-effectiveness analysis might be validated 
[36,42].  One of the studies in the review made an attempt to ‘validate’ its model by 
comparing some of the intermediate results of the analysis with the results of published 
studies.  Tosteson et al undertook several of these comparisons [81]: 
 
•  the cumulative incidence of fracture without interventions; 
•  the average age at first hip fracture for women with no previous hip fracture; 
•  reduction in hip fracture risk for particular treatment durations. 
 
Developing methods to validate decision models is likely to be an important part of this form 
of cost-effectiveness in the future, and this should be explicitly considered when planning 
further research in this area. 
 CHE Discussion Paper 169   23
4. CONCLUSIONS 
This document has reviewed economic evaluation studies relating to interventions to prevent 
and treat osteoporosis.  A total of 16 studies was identified, all cost-effectiveness analyses 
and all based on decision analytical techniques.  The use of interventions for fracture in this 
area can be divided in those used for primary prevention, in individuals who are at no 
apparent elevated risk of fracture, and in secondary prevention where individuals have some 
degree of elevated risk.  Often studies use the term ‘treatment’ to refer to the use of 
interventions to prevent fracture in individuals at markedly higher risk of fracture (usually 
characterised by low BMD and a previous fracture).  In the review, seven studies looked at 
primary prevention only, seven looked at both primary and secondary prevention and two 
looked at treatment of established osteoporosis.  In general, interventions were more likely to 
be considered cost-effective if they focused on individuals at higher risk of fracture.  Most 
studies focus on the evaluation of HRT (11/16). 
 
The development of the models over the 18 years since the publication of the first study [85] 
illustrates how clinical and epidemiological knowledge in the area has increased.  To a lesser 
extent, the development of the models also reflects changes regarding what is considered 
good practice in model-based economic evaluation.  Many of the studies in the review show 
important methodological limitations which have been described in this report.  These 
include the use of health state preferences (utilities) which, with a couple of exceptions, are 
not based on a formal elicitation process with patients or members of the public, and the 
inappropriate use of cost-effectiveness decision rules.  Future analysis in this area will 
hopefully be strengthened by understanding these weaknesses.   
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Appendix: Data tables for economic evaluations included in the review (see list of abbreviations at the end of the tables) 
 
Study Comparators  Methods  of 
evaluation 
Effects considered  Methods relating to baseline estimates  Methods relating to effects of 
interventions 







1. ORT for life 
from 50 years 
2. ORT from 50 to 
65 years 
3. ORT from 65 
years 
4. Dietary calcium 
supplements + 
exercise 
















• Cycle length: 1 
year 
• Deterministic 
• 50 year  time 
horizon 







• Hip fracture 
• Stroke 
• IHD 
• Breast cancer 
• Endometrial cancer 
Incidence: 
• Hip fracture: mathematical function 
related to age and BMD (Melton et al); 
distribution of BMD from Melton et al 
‘validated’ in Australian pop’n.  
• IHD: provincial data and MONICA study 
• Endometrial cancer: Australian cancer 
registry 
• Hysterectomy: Australian provincial data 
• Probability of entry into a nursing home 
after hip fracture (Australian data) 
• Age-specific probability of entry to 




• Case fatality rates from hip fracture (by 
age: 2%-20%) (Australian pop’n data) 
• From IHD and breast cancer (Australian 
admin’ve data) 
• From endometrial cancer (Australian 
cancer registry) 
• Residual from Australian life tables minus 
disease-specific rates. 
   
• Effect on BMD: ORT prevents bone 
loss while on therapy; for ORT for 15 
years, protective effect lasts for total 
of 20 years; for calcium, BMD loss 
50% that of no intervention 
• IHD RR: 0.50; same effect on 
incidence and mortality 
• Breast cancer RR: 1.02
x, where x is 
the duration of exposure to ORT; 
same effect on incidence and 
mortality 
• Endometrial cancer RR: 8.0; effect on 
incidence only, not mortality 
• Stroke: no effect in base-case 
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[1991 Australian $] 
• Hip fracture: 
7211/fracture 
• IHD: 5735/case + 
316/year 
• Breast cancer: 
10366/case 
• Endometrial cancer: 
8093 + monitoring 
• Nursing home: 82 per 
bed-day 
• Oestrogen: 108/year 
including 2 annual GP 
visits 
• Calcium: 85/year 
• Exercise: 4/week 
 
Based on authors’ judgement: 
• Women returning home after 
fracture (0.9) 
• Women going to nursing home 
after fracture: 0.67 
 
• ICER intervention 2 relative to 
intervention 1: 8725/life-year 
gained 
• ICER intervention 3 relative to 
intervention 1: 32185/life-year 
gained 
• Treatment from age 65 most cost-
effective because treatment 
focuses on the years when BMD 
losses are greatest 




• Protective effect of ORT 
on IHD 
• Cost-effectiveness of 
intervention 4 sensitive to 
cost and effects 
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Effects considered  Methods relating to baseline 
estimates 

















2. ORT in women 
with symptoms 
of osteoporosis. 







1.  50-60 years 
2.  50-65 years 
3.  55-70 years 
• CEA (QALYs) 




• lifetime  time 
horizon. 
• 5% (costs) and 0% 
benefits discount 
rates. 
• Perspective: health 
service. 
• Hip and wrist fracture. 
• Endometrial cancer 
• Gallbladder disease. 
• Uterine bleeding. 
 
[Breast cancer in 
sensitivity analysis.] 
Incidence: 
• Hip and wrist fractures: age-specific 
incidence taken from literature; 
adjusted upwards to allow for greater 
risk of fracture in women with 
osteoporosis (assumed to be 10% by 
55 years and 20% by 65 years). 
• Endometrial cancer: age-specific 
incidence based on national cancer 
survey.  Adjusted for an estimated 
30% hysterectomy prevalence. 
• Cholecystectomy: age-specific 




• Fatality rate from hip fracture: 10%. 
• Fatality rate from cholecystectomy : 
0.28-1.3%. 
• Fatality rate from endometrial 
cancer: 10%. 
• Fatality rate from D&C: 0.1% 
• Years lost assessed against US life-
tables. 
   
• Hip and wrist fracture: RR for women 
not on ORT of 3.0 during treatment, 
2.0 for an equal number of years 
afterwards, then a return to 1.0. 
• Endometrial cancer: RR for ORT 8.0 
from 5 years after start of ORT until 5 
years after. 
• Cholecystectomy: RR for ORT 2.5 
from 5 years after start of ORT until 5 
years after.  
• Uterine bleeding: risk of 0.3% per 
month for first 2 years of treatment. 
• Breast cancer: RR of 1.5 in ORT 
(sensitivity analysis only). 
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• Hip fracture: 6000. 




• D&C (uterine 
bleeding): 
500/case. 






• Symptoms: 0.99. 
• Hip fracture: 0.95 for 
life. 
• Endometrial cancer: 
give up 1 year of 
remaining life to 
avoid. 
 
• In symptomatic women with 
uterus: cost/QALY of 7420-
18160.   
• In terms of life-years, ORT 
reduces life-years (dominated). 
• In women with osteoporosis: 
cost/QALY of 5460-15100 
• Highly cost-effective in women 
with uterus or osteoporosis. 
• In symptomatic women with 
uterus depends on quality weight 
for symptoms. 




• RR of breast cancer. 
• RR of fracture. 
No consideration of possible 
protective effects on IHD. 
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3. Universal CRT. 
 
 
• CEA (life-years 
and QALYs). 




• Lifetime  time 
horizon. 







• Hip fracture. 
 
[Breast cancer and 
IHD in sensitivity 
analysis.] 
Incidence: 
• Fracture as a function of BMD: 
distributions of initial BMD from survey; 
loss of BMD estimated by quadratic 
function of age; regression model to 
estimate risk of hip fracture as function of 
age and BMD based on population survey. 
• Age-specific rates of entry into nursing 




• Hip fracture: age-specific death rates after 
fracture from population survey (assuming 
50% due to hip fracture). 
• IHD: death rates based on life-tables 
(sensitivity analysis only). 
 
• Hip fracture: no bone loss on CRT for 
duration of therapy, then loss at same 
rate as 50 year-old when therapy 
stopped. 
• IHD: 25-57% reduction in death rate 
(sensitivity analysis only). 
• Breast cancer; 25% increase in risk 
(sensitivity analysis only). 
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Study  Cost inputs  Utility assumptions  Main base-case results  Sensitivity analysis  Comments 
Tosteson 
et al  
[1990] 
[81] 
[1987 US $]: 
• Hip fracture: 10250-
12100/case. 
• CRT: 200/year. 
• Nursing home: 
25550/year. 
• Screening: 150. 
 
 
Use of Hillner et al’s [1986] 
values#: 
• 0.8 after hip replacement. 
• 0.4 for long-term nursing home 
care. 
• 0.95 for uncomplicated hip 
replacement . 
 
• Cost per QALY of screening: 
4200-37800 depending on 
screening threshold (<0.9=4200; 
<1=8,600; <1.1=37,800). 
• Cost per QALY of universal: 
144000. 
Type of analysis: simple 




• Breast cancer risks; 
increases ICER of 
universal. 
• IHD protection: universal 
may become dominant 
depending on cost 
savings. 
• Risk of fracture given 
bone loss. 




   30
Appendix: Data tables cont’d 
Study Comparators  Methods  of 
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durations and age 
ranges: 
• 5 years (50-55 
years) 
• 10 years (50-60 
years) 





• CEA (QALYs). 




• Lifetime  time 
horizon. 







• Hip fracture 
• Stroke 
• IHD 
• Breast cancer 
• Endometrial cancer 
Incidence: 
• Hip and wrist fracture: age-specific 
incidence from surveys. 
• Breast cancer: age-specific incidence from 
surveys adjusted for prevalence of 
oestrogen use. 
• Endometrial cancer: age-specific incidence 
from surveys adjusted for prevalence of 
hysterectomy and oestrogen use. 
• Endometrial hyperplasia: 0.75%/year (same 
as in CRT). 





• Endometrial cancer: case fatality rate: 10% 
in five years with monitoring and 85% 
without monitoring. 
• Breast cancer: relative survival rates from 
National Cancer Institute. 
• Gallbladder disease (cholecystectomy): 
case fatality rates 0.28-1.31% depending 
on age. 
Hip fracture: case fatality rate of 18%. 
 
• Hip and wrist fracture: RR of 0.4-1.0 
depending on ages treated and age at 
risk. 
• Endometrial cancer: RR of 1-8 
depending on ages treated and age at 
risk in ORT; RR of 1.0 in CRT. 
• Endometrial hyperplasia: 9%/year in 
ORT and 1.5%/year in CRT.  First 5 
years of treatment only. 
• Gallbladder disease: RR of 2.5 with 
ORT. 
• Uterine bleeding: 24%. 
• Uterine bleeding: 5% in ORT; 2.5% in 
CRT or no treatment. 
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[1982 US $] 
• ORT: 85/year. 
• CRT: 145/year. 
• Monitoring (biopsy); 
115 (ORT), 57 (CRT). 
• Endometrial hyperplasia 
(D&C): 500/case. 
• Endometrial bleeding 
(biopsy): 115/year of 
bleeding. 
• Endometrial cancer: 
3250. 
• Breast cancer; 4000. 
• Hip fracture: 7400. 
• Wrist fracture: 250. 
• Cholecystectomy: 3500. 
 
Based on authors’ judgement: 
• Symptoms: 0.99 (women on 
ORT get 0.01 increase in 
QALYs for duration of 
treatment; 50% of that for 
women on CRT. 
• Endometrial cancer: 0.8 for 5 
years. 
• Hip fracture: 0.9 for rest of life. 
 
• Costs per QALY: ORT: 130000 
(vs. CRT) 
• Costs per QALY: CRT: 42000 
(aged 50-55 years), 29000 (50-
60), 24000 (50-65 years) (vs. no 
treatment). 
• ORT reduced life expectancy but 
outweighed by quality of life 
improvements with symptoms. 
• CRT increased life expectancy. 




• ICER of CRT sensitive 
to the utility loss of 
continued menstrual 
bleeding relative to 
reduction in menstrual 
symptoms. 
 
• No consideration 
of protective 
effect of ORT on 
IHD. 
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durations and age 
groups: 
1. 5 years (50-55 
years). 
2. 10 years (50-60 
years). 





1. Presence of 
menopausal 
symptoms. 






• CEA (QALYs). 
• State transition 
model (variable 
probabilities). 
• Cycle length: 1 
year. 
• Deterministic. 
• Lifetime  time 
horizon. 







• Hip fracture 
• Wrist fracture. 
• IHD (AMI). 
• Endometrial cancer 
• Uterine bleeding. 
Incidence: 
• Hip fracture: annual average (age-specific) 
incidence from national data sources. 
• Wrist fracture: annual incidence from 
Norwegian data source. 
• Breast and endometrial cancer: age-specific 
incidence rates from national data sources. 
• IHD (AMI): incidence in 5-year age groups 
from published study. 
• Hysterectomy prevalence of 21% at age 50. 
 
Mortality: 
• General: age-specific rates for 5-year 
periods from life-tables. 
Breast cancer, hip fracture and endometrial 
cancer: from published survival rates using 
DEALE technique. 
• IHD: three alternative RRs for deaths 
from AMI: 1.0, 0.75, 0.5.  Assumed to 
last from 5 years after start of therapy 
to 5 years after finish. 
• Fracture: RRs of 0.4-0.8 depending on 
age. 
• Endometrial cancer: RRs of 2.0 to 8.0 
depending on age for ORT. 
• Unscheduled bleeding: annual rates of 
9% with hyperplasia and 23% without 
hyperplasia (for ORT) and 2% with 
hyperplasia and 12% without 
hyperplasia (for CRT and untreated 
women) 
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[1988 Australian $] 
• ORT: 71/year. 
• CRT: 124/year. 
• Consultation: 55/year 
(both). 
• Endometrial biopsy: 
91/year (ORT only). 
• Hip fracture: 7695/case. 
• Wrist fracture: 440/case. 
• D&C (for uterine 
bleeding): 593/case. 
• Endometrial cancer: 
4370/case. 
• Breast cancer: 
5807/case. 
• AMI: 5214/case. 
 
• Based on Weinstein and Schiff  
(judgement).   
• Symptoms: 0.99 (women on 
ORT get 0.01 increase in 
QALYs for duration of 
treatment; 50% of that for 
women on CRT. 
• Endometrial cancer: 0.8 for 5 
years. 
• Hip fracture: 0.9 for rest of life. 
• In addition to Weinstein and 
Schiff, AMI given same utility as 
hip fracture (0.9 for rest of life).  
• Benefit of ORT on menopausal 
symptoms assumed to be halved 
with CRT. 
 
• Costs/QALY: in symptomatic 
women: 9500-17500 (ORT), 9820-
34700 (CRT). 
• Costs/QALY: in women without 
symptoms: 45800- dominated 
(ORT); 26100-1450000 (CRT). 
• Costs/QALY: in women with 
hysterectomy: 6510-1020000 
(ORT). 
• Lifetime net increments in costs 
mainly relate to HRT and 
consultations. 
• Net QALY improvements mainly 
relate to improvements in 
symptoms - thus lower ICERs in 
symptomatic women. 
• In non-hysterectomised women, 
use of ORT may not be worth 
increased risk of endometrial 
cancer unless >50% reduction in 
risk of AMI. 
   




• Treatment duration. 
• Presence of menopausal 
symptoms. 
• Presence of side effects 
from progestogen. 
• Cardiac benefits. 
Poor use of decision 
rules. 
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Effects considered  Methods relating to baseline estimates  Methods relating to effects of 
interventions 










2. No treatment. 
 




3. No treatment. 
 
[In all cases, 10 
years treatment 
in women aged 
50 years.] 
• CEA (life-years 
and QALYs). 




• Lifetime time 
horizon. 







• Fractures (wrist, 
vertebral and hip). 
• Stroke. 
• IHD. 
• Breast cancer. 
• Endometrial cancer. 
• Hysterectomy. 
Incidence: 
• Fracture rates based on published surveys. 
• Breast and endometrial cancer rates and 
IHD based on UK hospital admissions 
(age-specific). 




• For no treatment, cancers and IHD: UK 
mortality statistics. 
• Hip fracture: 25% case fatality. 
 
• Fractures: 20% reduction in first 5 
years and 60% reduction after that.  At 
end of treatment, effect lasts for as 
long as the treatment period. 
• Breast cancer: 0% increase in risk 
after 5 years, 30% after 10 years, 50% 
after 15 years. At end of treatment, 
effect lasts for as long as the treatment 
period. 
• Endometrial cancer: 6-fold increase in 
risk from 5 years after start of ORT 
treatment until 5 years after finish.  No 
increase in risk for CRT. 
• IHD: 25% reduction in risk after 5 
years, 50% reduction after 10 years 
(ORT).  50% effect of this effect in 
CRT. At end of treatment, effect lasts 
for as long as the treatment period. 
• Stroke: 25% reduction in risk with 
ORT, 12% reduction with CRT. 
• Hysterectomy: 2-fold increase in risk 
of hysterectomy/D&C in ORT, 25% 
increase with CRT (for treatment 
period only). 
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• ORT: 12/year. 
• CRT: 48/year. 
• GP visits: 14/year. 








(GPs), depending on 
age. 
• Other costs estimated 
using age-specific 
lengths of stay 
multiplied by cost per 
day of 135. 
   
Based on authors’ judgement: 
• 0.95 severe menopausal 
symptoms. 
• 0.99 mild menopausal 
symptoms. 
 
• Cost per life-year gained: 2900 in 
women with no uterus (ORT); 
8300 in women with uterus 
(ORT); 14400 (CRT). 
• Cost-effective in hysterectomised 
women and in women with severe 
symptoms. 
Type of analysis: simple 




• Increase in quality of life 
as a result of menopausal 
symptoms. 
• IHD protection. 
• Whether CRT removed 
IHD protective effect. 
• Duration of treatment. 
 
Interestingly 
include cost of 
health care during 
life-years saved.   36
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Study Comparators  Methods  of 
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1. In women with 
uterus: ORT vs. 
no treatment. 
2. In women 
without uterus: 





1. 10 years. 




Same model as 





• Hip fracture 
• IHD 
• Breast cancer 
Incidence: 
• Hip fracture: Estimated relationship 
between BMD and fracture risk based on 
population-based survey.  BMD levels 
modelled as function of age.  Hip fracture 
modelled as a function of BMD and age. 
• Breast cancer: same assumptions as 
Weinstein and Schiff. 
 
Mortality: 
• After hip fracture modelled as a function of 
age based on population-based survey. 
• IHD: baseline death rate from US life-
tables. 
• Breast cancer: same assumptions as 
Weinstein and Schiff. 
• Death from other causes from US life-
tables. 
 
• No bone loss when on HRT; when end 
therapy bone loss same as at 
menopause. 
• Breast cancer: RR of 1.36 from 2 years 
after start of therapy to 2 years after 
(ORT only). 
• IHD:  RR of 0.5 for IHD deaths for as 
long as treatment lasts (ORT only). 
• Risk of being in a nursing home after 
hip fracture modelled as a function of 
age from national survey data. 
• Risk of being in a nursing home for 
other reasons from a published study. 
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• HRT (including 
monitoring and 
physician visits): ORT= 
193/year, 
CRT= 250/year. 
• Hip fractures: 12810 
(50-59 years) to 15125 
(80-89). 
• Breast cancer: 7970/case 
(assumed non-invasive). 
• Nursing home: 
31940/year. 
 
[No allowance for cost 
savings from IHD.] 
 
Based on Hillner et al [1986]#. 
• Hip fracture: 0.36 for nursing 
home care; 0.95 for 
uncomplicated hip fracture; 0.76 
disability due to hip fracture; 
0.8 long-term disability; 0.4 
long-term nursing home care. 
• 0.997 for side effects of HRT. 
 
 
• Gain in life expectancy due to 
reduction in fractures similar to 
loss due to breast cancer. 
• Biggest effect on life expectancy 
comes from IHD risks. 
• Side effects are biggest quality of 
life factor. 
• If IHD risk reduction excluded and 
quality of life changes from side 
effects included, all options have a 
net loss in QALYs. 
• ORT (in women without uterus): 
cost/QALY: 7010-9020; without 
quality of life effect of side effects; 
9930-14940. 
• CRT: (in women with uterus): 
cost/QALY: 32660-33780; without 
quality of life effect of side effects; 
>150000. 
   
Type of analysis:  




• IHD risks. 
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For women aged 
50 years: 
1. ORT for 5 
years. 
2. CRT for 5 
years. 









Same as Weinstein and 
Schiff [1983]. 
 
Same as Weinstein and Schiff [1983]. 
Except: 
• Hip fracture: modelled as a function of 
BMD and age; distribution of BMD at 50 


















Same as Weinstein and 
Schiff [1983]. 
 




• ORT for 5 years: cost per QALY 
of 72100 in asymptomatic women 
and 12600-33100 in symptomatic 
women depending on symptom 
relief. 
• CRT for 5 years dominates ORT 
for 5 years assuming quality of life 
differences are minimal. 
• CRT for 15 years: cost/QALY of 
22650. 
   
Type of analysis:  
simple sensitivity analysis 
and scenario analysis. 
 
Key variables: 
• RR of hip fracture. 
• Quality of life effects of 
symptoms. 
 
No consideration of 
protective effect of 
ORT on IHD. 
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1. In women with 
uterus: ORT vs. 
no treatment. 
2. In women 
without uterus: 








• CEA (life-years 
and QALYs). 




• Lifetime  time 
horizon 









• Breast cancer. 
• Endometrial cancer. 
Same assumptions as Daly et al [1992].  Same assumptions as Daly et al [1992] 
except: 
• No risk of endometrial cancer in 
women with uterus because of use of 
CRT. 
• Hysterectomy/D&C: 25% risk in 
women with uterus taking CRT. 
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Same assumptions as Daly 
et al [1992]. 
 
[1992-3 UK £] 
• ORT: 24/year. 
• CRT: 53/year. 
• GP visits: 23/year. 
• Wrist fracture: 170/case. 
• Vertebral fracture: 170-
420/case (depending on 
age). 
• Hysterectomy: 1610-
3810/case (depending on 
age). 
• Breast cancer: 1950-
6910/case (depending on 
age). 
• IHD: 1540-4750/case 
(depending on age). 
• Stroke: 4000-12010 
(depending on age). 
• Hip fracture: 2230-6210 
(depending on age). 
• Health service costs of 
life-years saved: 361-
2363 (depending on 
age). 
 
Based earlier empirical study by 
same authors.  Assumes: 
 
• 90% have relief of symptoms 
(lasting 5 years). 
• 5% side effects (only treated for 
6 months). 
• 5% no change on quality of life. 
 
Cost /QALY in mildly symptomatic 
women:  
• ORT: 310 (5 year treatment) to 
660 (20 years). 
• CRT: 550 (5 year treatment) to 
1250 (20 years). 
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1. Calcium (5 
years). 
2. Etidronate (5 
years). 
3. Calcitonin (5 
years). 




1.  All women. 
2.  High risk 






• CEA (fractures 
prevented). 




• Lifetime  time 
horizon. 
• 5% discount 
rate on costs, 






• Hip fracture 
• IHD 
• Breast cancer 
 
Incidence: 
•  Fractures (hip, forearm, vertebral): age-
specific incidence based on 
hospitalisation (for hip) and published 
sources (for others). 
•  Breast cancer: age-specific incidence 
based on Danish cancer registry. 




•  Underlying age-specific rates based on 
Danish data. 
 
• Optimistic (O) and pessimistic (P) 
assumptions for each treatment, and 
‘realistic’ for HRT (R). 
 
Fracture (RRs) 
• Calcitonin: O=0.23 for life; P=0.70 
from 5 years then linear decrease until 
year 25. 
• Etidronate: O=0.5 for life; P=0.50 for 
5 years than linear decrease until year 
25. 
• Calcium: O=0.5 for life; P=0.75 for 5 
years than linear decrease until year 
25. 
• HRT: O=0.50 (0-30 years); P=0.75 (0-
10 years) and 0.85 (10-15 years); 
R=0.50 (0-10 years); linear decrease 
(10-35 years). 
 
• Breast cancer (HRT only): O=0 (0-10 
years); 1.30 (10-20 years); 0 (20 + 
years).  P=linear increase (0-10 years); 
1.30 (10-20 years); 0 (20 + years).  
R=0 (0-10 years); 1.30 (10-20 years); 
0 (20 + years). 
• IHD (HRT only): O=0.50 (0-30 years); 
P=0.65 (0-10 years), 0.75 (10-15 
years); R=0.65 (0-30 years). 
   42
Appendix: Data tables cont’d 






• Calcitonin: 8975/year. 
• Etidronate: 1919/year. 
• Calcium: 2369/year. 
• HRT: 1061-1748/year. 
• Hip fracture: 
146641/case. 
• Forearm fracture: 
6592/case. 
• Vertebral fracture: 
3794/case. 




• Hospital admission for 
IHD: 8400/day (day 1); 
2000/day (after day 1).  
Length of stay is a 




• Etidronate has lowest average 
cost-effectiveness ratio and 
calcitonin the highest. 
• Screening approach has lower 
average cost-effective ratio than 
population-based approach. 
Type of analysis: simple 
one-way. 
 
Key variables:  
• Treatment efficacy. 
• Drug acquisition costs. 
• Compliance. 
 
Inappropriate use of 
average cost-
effectiveness ratios. 
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Jonsson et al 








1. No treatment. 
2. Treatment for 
5 years for 62-
year old 
woman with 
BMD below 1 
















• Lifetime time 
horizon. 










• Risk of fracture is modelled as a function 
of a range of variables including BMD.   
• At 1SD below the mean, the RR of hip 
fracture is 2.16. 
 
Mortality: 
• Underlying mortality from general 
population statistics. 
• Hip fracture mortality risks in first year 
after fracture: <65 years of age, 0 excess 
risk of death; 65-74 10% excess risk; 75-
84 20% excess risk; 85+ 50% excess risk. 
No excess mortality from other fractures. 
• Fractures: 50% reduction in risk of 
fracture. 
• After a hip fracture, it is assumed that 
40% remain in full health, 32% near 
normal functioning, 8% severely 
handicapped, 20% die by year 1. 
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• Hip fracture: 
156000/case  in first 
year. 
• Spine: 16000/case. 
• Wrist/shoulder: 
4000/case. 
• Nursing home: 
200000/year. 
• BMD measurement 
350/test. 
• Indirect costs of 
treatment: 250/year/ 
• Intervention (drug): 
6000/year. 
 
From Hillner et al [1986]: 
• After hip fracture: 0.95 
(uncomplicated); 0.76 
(disability); 0.36 (requiring 
nursing home); 0.8 (long-term 
disability); 0.4 (long-term 
nursing home).  Average of first 
year: 0.82 based on probability 
of outcomes. 
 
As alternative set of values: Rosser 
based on original scaling: 
• First year average after hip 
fracture: 0.83. 
• Following years: 0.99 if return to 
full function and 0.85 if severely 
handicapped. 
 
As a further alternative, Rosser 
based on Swedish re-scaling: 
• First year average after hip 
fracture: 0.56. 
• Following years: 0.90 if return to 
full function and 0.35 if severely 
handicapped. 
 
Base-case uses 0.80 in first year 
and 0.40 after for hip, and 0.90 or 
0.95 in year 1, then return to full 
function (1.0). 
 
• Costs per hip fracture avoided: 
60000-1000000 for 5 year 
treatment depending on reduction 
in annual fracture rate, annual risk 
of fracture and treatment cost. 
• Cost per life-year gained: 190000-
819000 depending on discount 
rates. 
• Cost per QALY: 92000-318000 
depending on discount rates and 
quality of life weights. 




• Discount rates. 
• Effectiveness of 
treatment. 
• Cost of treatment. 
• Quality of life loss due to 
side effects of drugs. 
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1. Calcitonin for 1 
year in women 
over 50 years 
of age. 




risk only based 
on screening.] 
 




No further details. 
 
 
• Hip fracture  Incidence: 
• Hip fracture: 2.51/1000 (overall); 













[US $, 1995] 
• Calcitonin: 1907/year 
• Hip fracture: 
82508/case. 




• Cost per hip fracture avoided: 
2367987 for population; 838,120 
for high-risk women based on 
screening. 
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• CEA (vertebral 
fractures 
avoided). 
• Decision tree.  
• Deterministic. 
• 1 year time 
horizon. 






• Vertebral fractures.  Incidence: Incidence of further vertebral 
deformation in women with existing 
vertebral fracture.  Taken from control 
groups of trials of osteoporosis treatments.  
Assumed 33.7% annual incidence. 
 
• Reduction in fractures 53-60% 
depending on treatment,  Based on 
trials where a statistically significant 











Annual drug costs ranging 
from Premarinm at 26.38 




Cost per vertebral fracture avoided:  
•  138-680 HRT 
•  1880 etidronate 
•  9075-25,013 salmon calcitonin 
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Appendix: Data tables cont’d 
Study Comparators  Methods  of 
evaluation 












1. Screening for 
low BMD and 
HRT in high-
risk.  





Two age groups: 
1. 50 years. 









• Time horizon: 
until 90 years 
of age. 







• Hip fracture 
• IHD (AMI) 
• Breast cancer 
• Endometrial cancer 
• Gallstones. 
Incidence: 
• Hip fracture: modelled as a function of 
BMD and age from SOF study.  BMD 
given an initial distribution and annual 
decline with out treatment. Assumed to be 
normally distributed. 




• Hip fracture: elevated risk of death (as 
function of age) in year after fracture, then 
same as general population. 
• Breast cancer: age of death from tumour 
registry (by stage). 
• Endometrial cancer: when on HRT age of 
death same as general population.  When 
not on HRT, age of death set by tumour 
registry. 
• Gallstones: no excess mortality. 
• Risk of death from AMI same as in general 
population. 
 
• Hip fracture: HRT eliminates bone 
loss while on treatment after which 
rate of loss same as menopause. 
• Breast cancer: RR of 1.35 after 10 
years treatment and this remains until 
death. 
• IHD (AMI): RR for ORT of 0.50 and 
for CRT of 0.80 for duration of 
therapy. 
• Endometrial cancer: RR for ORT of 
3.5 for 10 years. 7.0 after 10 years.  
Returns to 1.0 after treatment.  No 
increased risk for CRT. 
• Gallstones: RR of 2.5. 
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[1993 US $] 
• ORT: 269/year. 
• CRT: 258/year. 
• BMD screening: 
150/test. 
• Cost of fatal AMI: 
14470/case. 
• Cost of non-fatal AMI: 
74217/case. 
[Ratio of non-fatal to 
fatal AMI: 2.6] 
• Hip fracture: 22912. 
• Cholecystectomy: 
11160. 
• Breast cancer: 45043-
78153 (by stage). 
• Endometrial cancer 
(without HRT): 6000. 
• Endometrial cancer 
(with HRT): 15702-




• Mean costs per life-year gained 
for screening and ORT:22431-
151392 depending on duration of 
therapy and screening threshold. 
• Mean costs per life-year gained 
for population-based approach 
and ORT: 23334-126876 
depending on time on therapy. 
• Life-long therapy more cost-
effective. 
• CRT has lower ICERs because of 
lower protective effect regarding 
IHD. 
• Non-HRT drugs only have a 
chance of being cost-effective if 
used in established osteoporosis. 
Type of analysis: simple 1-




• Duration of therapy 
(compliance). 
• Protective effect against 
IHD (for ORT). 
 
Doubtful use of 
cost-effectiveness 
decision rules. 
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1. Vitamin D 
injection (for four 
years). 
2. Oral vitamin D 
and calcium (for 
three years). 
 
In 3 populations: 
1. Women with low 
BMD in the 
community. 
2. Women with low 
BMD in nursing 
homes, 




• CEA (fractures 
avoided). 
• Decision tree. 
• Deterministic 
• 3-4 year time 
horizon. 
• 6% discount rate 
(costs and effects). 





• Fractures  Incidence: 
• Fracture incidence from survey data in 
both general population and nursing 
homes. 
• General population (cumulative 4 
years); 11.25% all fractures and 5.4% 
hip alone. 
• Nursing home population  (cumulative 
4 years); 44% all fractures and 22% hip 
alone. 
• 21.6% of all hip fractures in women 
with BMI <20kg/m
2, (12.2% of the 
population). 
• Vitamin D injection: over four 
years, 25% reduction in all 
fractures; 22% in hip fractures. 
• Vitamin D and calcium: over three 
years, 21% reduction in all 
fractures and 28% in hip fractures. 
• In women with low BMI, Vitamin 
D for four years reduces  the 









• [UK £] 
• Vitamin D injection: 
28.10 over four years. 
• Oral vitamin D and 
calcium: 103/year. 
• Hip fracture: 5000. 
 
None.  •  Cost per hip fracture avoided 
(including cost of hip fractures) 
for oral vitamin D + calcium: 
£17379 in community; 1800 in 
community (low BMI); 4735in 
nursing homes; cost saving 
overall in nursing homes (low 
BMI). 
•  Cost per hip fracture avoided 
(including cost of hip fractures) 
for vitamin D injection: all 
options save costs overall. 
None.  Use of average 
cost-effectiveness 
ratios.   50
Appendix: Data tables cont’d 
Study Comparators  Methods  of 
evaluation 




















• CEA (QALYs) 
• State transition 
model (variable 
probabilities) 
• Cycle length: 1 
year 
• Deterministic 
• 50 year  time 
horizon 
• 0% discount rate 
as time horizon 
and sequencing 
identical for each 
option. 
 
• Hip fracture 
• Wrist fracture 
• Vertebral fracture. 
• Other fracture. 
Incidence: 
• Fractures modelled as a function of age 




• Hip fracture: 0.05. 
• No elevated risk from other fractures. 
Reduction in fracture rate: 
• Calcium + vitamin D: >=10% hip, 
>=10% vertebra, >=10% wrist, 
>=10% other. 
• Bisphosphonates: 50% hip, 
50%vertebra, 50% wrist, 0% other. 
• Calcitonin: 0% hip, 75% vertebra, 
0% wrist, 0% other. 
• HRT (5 year treatment): 25% hip, 
50% vertebra, 25% wrist, 25% 
other. 
• HRT (10 year treatment): 75% hip, 
75% vertebra, 75% wrist, 75% 
other. 
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[1992 US $] 




• Calcitonin: 740/year. 
• HRT (5 years): 
430/year. 
• HRT (10 years or 
more): 430/year. 
• Hip fractures: expected 
costs for first year: 
28242 (50-64 years), 
26227 (>=65) years); 
some disability in 27% 
600/year; moderate 
disability in 28% 
2400/year; nursing 
home in 7% 
27516/year.. 
• Wrist fractures: 1000 
(acute), 2400/year 
(dependency in 2%). 
• Vertebral fractures: 
1000 (acute); 
dependency in 5% 
2400/year. 
• Other fractures: 3266 
(acute). 
 
Based on authors’ judgement and 
published estimates: 
• QALYs losses varying posited 
for a range of possible outcomes 
from hip, wrist, vertebral and 
other fractures (e.g. the 
expected loss in QALYs during 
the year of a hip fracture were 
0.6183, implying a utility value 
for this year of 0.3817. 
 
For cost-effectiveness analysis, a 
monetary value of $30,000 per 
QALY employed. 
• Number of balance sheets 
presented detailing fractures rates 
and treatment and fracture costs 
with and without interventions. 
• Also use of nomograms to 
identify optimal management of 
individual women with particular 
characteristics. 
• As regards the use of testing for 
BMD, this should not be done on 
all women, but depend on each 
individual’s risk factors. 
• HRT is the most cost-effective 
treatment for osteoporosis. 
• The sub-groups on whom it 
should be used depend on BMD 




Type of analysis: scenario 
analysis. 
 
• Cost of the drugs. 
• QALY effects of side 
effects of drugs. 
 
This analysis was 
undertaken to 
inform clinicians 
about the optimal 
treatment of 
individual women. 
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Abbreviations used in data tables 
 
AMI  Acute myocardial infarction 
BMD  Bone mineral density 
BMI  Bone mineral index 
CEA Cost-effectiveness  analysis 
CRT  Combined (oestrogen plus progestogen) replacement therapy 
D&C  Dilatation and curettage 
ICER  Incremental cost-effectiveness ratio 
IHD  Ischaemic heart disease 
ORT  Oestrogen replacement therapy 
RR Relative  risk 
SD Standard  deviation CHE Discussion Paper 169   53
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